Merck & Co has announced the US launch of a mobile app designed to help and enhance communications between diabetes patients and educators. US-based Merck said the app known as map4health was ...

It's worth noting that the agreement has been forged a few months after Merck suffered a setback in its attempt to secure FDA approval for a potentially first-in-class drug for chronic cough ...

"It is integrated into everything that we do," says Merck's chief information and digital officer Dave Williams.

Merck & Co Inc (Symbol: MRK) presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by ...

DELUCA RICHARD ROBERT JR. Officer Conversion of Exercise of derivative security May 3, 2024 151,596 GUINDO CHIRFI Officer Conversion of Exercise of derivative security Aug 5, 2024 40,423 KLOBUCHAR ...

In my view, Merck's shares still look attractive for long-term investors. Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends ...

Merck's (MRK) monoclonal antibody clesrovimab shows cuts RSV infections by 60% in infants, with a strong safety profile. Read ...

Sept 25 (Reuters) - Merck (MRK.N), opens new tab said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial testing it in previously ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

In my view, Merck's shares still look attractive for long-term investors. Before you buy stock in Merck, consider this: ...